A phase 2, randomized, double-blind, double-dummy, Placebo-controlled, dose-ranging, dose-finding, parallelgroup study to assess efficacy and safety of PF-06865571 (DGAT2i) alone and when coadministered with PF-05221304 (ACCi) in adult participants with biopsy-confirmed nonalcoholic Steatohepatitis and fibrosis stage 2 or 3

Pfizer Inc0 sites0 target enrollmentTBD

ConditionsHealth Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified
Sponsor: Pfizer Inc
Status: Not yet recruiting
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

4 years ago

Study Type

Interventional

Investigators

Sponsor

Pfizer Inc

Eligibility Criteria

Inclusion Criteria

•(1\)Biopsy proven NASH with either F2 or F3 fibrosis, per NASH CRN definition
•(2\)BMI more than or equal to 22\.5kg/m2

Exclusion Criteria

•(1\)Evidence of other causes of liver disease such as Alcoholic steatohepatitis, (de)compensated cirrhosis, active viral hepatitis
•(2\)Any condition possibly affecting drug absorption \-Unstable concomitant medical conditions, based on medical history or screening laboratory results including\-
•(3\)unstable liver function tests, recent cardiovascular event(s) significant malignancies,

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed

Not Applicable

Phase II multi-centre study to evaluate efficacy, safety, and immunogenicity of GMZ2 candidate malaria vaccine in children aged 12 to 60 monthsMalariaPaediatrics

PACTR2010060002033537Statens Serum Intitute1,840

Active, not recruiting

Phase 2

Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Participants With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)onalcoholic Steatohepatitis

JPRN-jRCT2071210112Kamiya Makoto440

Active, not recruiting

Phase 1

A study to assess the safety and efficacy of Semaglutide and the fixed dose combination of Cilofexor and Firsocostat, alone and in combination, in subjects with Chirrhosis due to Nonalcoholic Steatohepatitis (NASH)onalcoholic Steatohepatitis (NASH)MedDRA version: 24.1Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]

EUCTR2021-001445-12-ESGilead Sciences, Inc.440

Active, not recruiting

Not Applicable

A Phase 2, Randomized, Double-Blind, Double-Dummy, Multicenter,Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of 2Dose Regimens of TP-434 Compared with Ertapenem in Adult Community-Acquired Complicated Intra-abdominal InfectionsCommunity-acquired complicated intra-abdominal infectionMedDRA version: 12.1Level: LLTClassification code 10056570Term: Intra-abdominal infection

EUCTR2010-022548-19-BGTetraphase Pharmaceuticals, Inc.200

Recruiting

Phase 2

A clinical study to estimate the safety, tolerability and efficacy of two medications for treatment of complicated intra abdominal infections in adults.

CTRI/2011/10/002076Tetraphase Pharmaceuticals Inc150